| Q-Med Has Entered into a Development and Commercialisation ...
STOCKHOLM, Sweden--(BUSINESS WIRE)--Feb 9, 2007 - Q-Med AB (STO:QMED) and Medy-Tox Inc., a South Korean biopharmaceutical company, have today entered into an agreement regarding collaboration with regard to botulinum toxin based biopharmaceuticals. This collaboration will allow Q-Med to develop and commercialise new generations of botulinum toxin products for both esthetic and therapeutic indications. Medy-Tox will support Q-Med with its extensive technology and know-how in the development of botulinum toxin and Q-Med will support Medy-Tox in the establishment of its new facilities. .
AstraZeneca cutting 3,000 jobs
AstraZeneca said Thursday it plans to cut 3,000 jobs over the next three years because of an anticipated slowdown in sales growth. Details of the job cuts were not disclosed. Based in London, the pharmaceutical giant (NYSE:AZN - News) has 65,000 employees worldwide. The company has its U.S. headquarters in Wilmington, Del., where it employs 6,000, and about 12,000 employees in the United States. The company also reported 2006 financial results Thursday that included a profit of $6 billion, a 28 percent over the previous year's earnings. AstraZeneca's lead products include Nexium, a heartburn drug ; Crestor, a treatment for high cholesterol; the schizophrenia drug Seroquel; Symbicort, an asthma therapy; and Arimidex, a breast cancer drug. Published February 1, 2007 by the Philadelphia Business Journal .
Strong Start for Axcan Pharma's Fiscal 2007, With Record Revenue ...
MONT-SAINT-HILAIRE, QUEBEC--(CCNMatthews - Feb. 8, 2007) - Axcan Pharma Inc. (TSX:AXP)(NASDAQ:AXCA) - today reported financial results for the first quarter of fiscal 2007, ended December 31, 2006 (all amounts are stated in U.S. dollars). Highlights for the quarter include:
- Revenue of $78.8 million, an increase of 11.6% compared to the first quarter of fiscal 2006
- Diluted income per share for the first quarter of 2007 amounted to $0.34, compared to diluted income per share of $0.19 a year earlier, a 78.9% increase
- Revenue guidance for fiscal 2007 increased to $307- $312 million
"We are pleased to report very strong performance for this first quarter with double-digit revenue and income growth, led by our strong base business and solid prescription growth for all our key products in both North America and Europe," stated Frank Verwiel, M.D., President and Chief Executive Officer of Axcan.
|
